Dr. Anderson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
520 Country Club Pkwy
Eugene, OR 97401Phone+1 541-683-5001Fax+1 541-683-1422
Education & Training
- University of ColoradoFellowship, Gynecologic Oncology, 2013
- Loyola University Medical CenterResidency, Obstetrics and Gynecology, 2006 - 2010
- University of Illinois College of MedicineClass of 2006
Certifications & Licensure
- OR State Medical License 2013 - 2025
- CO State Medical License 2010 - 2013
- IL State Medical License 2009 - 2010
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Start of enrollment: 2018 Oct 15
- Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Start of enrollment: 2021 Feb 22
Publications & Presentations
PubMed
- 134 citationsA Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov...Bradley J Monk, Christine Parkinson, Myong Cheol Lim, David M O'Malley, Ana Oaknin
Journal of Clinical Oncology. 2022-12-01 - 181 citationsAtezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT...Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli, Austin Miller, Charles K. Anderson
Journal of Clinical Oncology. 2021-04-23 - 162 citationsAvelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open...Eric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann, Amit M. Oza, Rebecca Kristeleit
The Lancet. Oncology. 2021-07-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: